Translating the genetics of cystic fibrosis to personalized medicine

Translational Research

Volumn 168, Issue , 2016, Pages 40-49

  Corvol, Harriet ^a,b,c   Thompson, Kristin E ^a,b   Tabary, Olivier ^a,b   le Rouzic, Philippe ^a,b   Guillot, Loïc ^a,b  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR PROTEIN, HUMAN;

CLINICAL GENETICS; CYSTIC FIBROSIS; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC VARIABILITY; HUMAN; INFECTION; INFLAMMATION; LUNG DISEASE; MODIFIER GENE; MORBIDITY; MORTALITY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; PROCEDURES;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PRECISION MEDICINE;

EID: 84973484038     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.04.008     Document Type: Review

References (71)

1. 1 Robinson, P., Cystic fibrosis. Thorax 56 (2001), 237–241.
2. 2 McCormick, J., Mehta, G., Olesen, H.V., et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 375 (2010), 1007–1013.
3. 3 Chignard, M., Ramphal, R., Basic research funding by philanthropic organizations: a case in point. Am J Respir Crit Care Med 188 (2013), 1376–1378.
4. 4 Weston, A.D., Hood, L., Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 3 (2004), 179–196.
5. 5 Bauer, D.C., Gaff, C., Dinger, M.E., et al. Genomics and personalised whole-of-life healthcare. Trends Mol Med 20 (2014), 479–486.
6. 6 Riordan, J.R., Rommens, J.M., Kerem, B., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989), 1066–1073.
7. 7 Rommens, J.M., Iannuzzi, M.C., Kerem, B., et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245 (1989), 1059–1065.
8. 8 Kerem, B., Rommens, J.M., Buchanan, J.A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245 (1989), 1073–1080.
9. 9 Cant, N., Pollock, N., Ford, R.C., CFTR structure and cystic fibrosis. Int J Biochem Cell Biol 52 (2014), 15–25.
10. 10 Sosnay, P.R., Siklosi, K.R., Van Goor, F., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45 (2013), 1160–1167.
11. 11 Castellani, C., Cuppens, H., Macek, M. Jr., et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7 (2008), 179–196.
12. 12 Ferec, C., Scotet, V., Beucher, J., Corvol, H., Genetics and modifier genes, atypical and rare forms. Arch Pediatr 19:suppl 1 (2012), S3–S7.
13. 13 Fanen, P., Wohlhuter-Haddad, A., Hinzpeter, A., Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. Int J Biochem Cell Biol 52 (2014), 94–102.
14. 14 Berwouts, S., Morris, M.A., Girodon, E., Schwarz, M., Stuhrmann, M., Dequeker, E., Mutation nomenclature in practice: findings and recommendations from the cystic fibrosis external quality assessment scheme. Hum Mutat 32 (2011), 1197–1203.
15. 15 Cutting, G.R., Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 16 (2015), 45–56.
16. 16 Grody, W.W., Cutting, G.R., Klinger, K.W., et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 3 (2001), 149–154.
17. 17 Watson, M.S., Cutting, G.R., Desnick, R.J., et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 6 (2004), 387–391.
18. 18 Palomaki, G.E., Fitzsimmons, S.C., Haddow, J.E., Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med 6 (2004), 405–414.
19. 19 Hoegger, M.J., Fischer, A.J., McMenimen, J.D., et al. Cystic fibrosis. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 345 (2014), 818–822.
20. 20 Sallenave, J.M., Phagocytic and signaling innate immune receptors: are they dysregulated in cystic fibrosis in the fight against Pseudomonas aeruginosa?. Int J Biochem Cell Biol 52 (2014), 103–107.
21. 21 Cohen, T.S., Prince, A., Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 18 (2012), 509–519.
22. 22 Stoltz, D.A., Meyerholz, D.K., Pezzulo, A.A., et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med, 2, 2010, 29ra31.
23. 23 Bronsveld, I., Bijman, J., Mekus, F., Ballmann, M., Veeze, H.J., Tummler, B., Clinical presentation of exclusive cystic fibrosis lung disease. Thorax 54 (1999), 278–281.
24. 24 Bronsveld, I., Mekus, F., Bijman, J., et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 108 (2001), 1705–1715.
25. 25 Bronsveld, I., Mekus, F., Bijman, J., et al. Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology 119 (2000), 32–40.
26. 26 Mekus, F., Ballmann, M., Bronsveld, I., Bijman, J., Veeze, H., Tummler, B., Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res 3 (2000), 277–293.
27. 27 Mekus, F., Ballmann, M., Bronsveld, I., et al. Cystic-fibrosis-like disease unrelated to the cystic fibrosis transmembrane conductance regulator. Hum Genet 102 (1998), 582–586.
28. 28 Mekus, F., Laabs, U., Veeze, H., Tummler, B., Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet 112 (2003), 1–11.
29. 29 Cutting, G.R., Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 1214 (2010), 57–69.
30. 30 Guillot, L., Beucher, J., Tabary, O., Le Rouzic, P., Clement, A., Corvol, H., Lung disease modifier genes in cystic fibrosis. Int J Biochem Cell Biol 52 (2014), 83–93.
31. 31 Weiler, C.A., Drumm, M.L., Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol, 4, 2013, 40.
32. 32 Corvol, H., Boelle, P.Y., Brouard, J., et al. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol 43 (2008), 1224–1232.
33. 33 Drumm, M.L., Konstan, M.W., Schluchter, M.D., et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353 (2005), 1443–1453.
34. 34 Chalmers, J.D., Fleming, G.B., Hill, A.T., Kilpatrick, D.C., Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 21 (2011), 271–282.
35. 35 Beucher, J., Boelle, P.Y., Busson, P.F., Muselet-Charlier, C., Clement, A., Corvol, H., AGER-429T/C is associated with an increased lung disease severity in cystic fibrosis. PLoS One, 7, 2012, e41913.
36. 36 Corvol, H., Beucher, J., Boelle, P.Y., et al. Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros 11 (2012), 63–67.
37. 37 Wright, F.A., Strug, L.J., Doshi, V.K., et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43 (2011), 539–546.
38. 38 Griesenbach, U., Alton, E.W., Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 22 (2013), R52–R58.
39. 39 Alton, E.W., Boyd, A.C., Cheng, S.H., et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax 68 (2013), 1075–1077.
40. 40 Kim, H., Kim, J.S., A guide to genome engineering with programmable nucleases. Nat Rev Genet 15 (2014), 321–334.
41. 41 Zhang, F., Wen, Y., Guo, X., CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet 23 (2014), R40–R46.
42. 42 Schwank, G., Koo, B.K., Sasselli, V., et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13 (2013), 653–658.
43. 43 Wong, A.P., Bear, C.E., Chin, S., et al. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol 30 (2012), 876–882.
44. 44 Du, M., Jones, J.R., Lanier, J., et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med (Berl) 80 (2002), 595–604.
45. 45 Sermet-Gaudelus, I., Renouil, M., Fajac, A., et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med, 5, 2007, 5.
46. 46 Clancy, J.P., Bebok, Z., Ruiz, F., et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163 (2001), 1683–1692.
47. 47 Wilschanski, M., Famini, C., Blau, H., et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:3 Pt 1 (2000), 860–865.
48. 48 Wilschanski, M., Yahav, Y., Yaacov, Y., et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349 (2003), 1433–1441.
49. 49 Du, M., Liu, X., Welch, E.M., Hirawat, S., Peltz, S.W., Bedwell, D.M., PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 105 (2008), 2064–2069.
50. 50 Hirawat, S., Welch, E.M., Elfring, G.L., et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47 (2007), 430–444.
51. 51 Kerem, E., Hirawat, S., Armoni, S., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372 (2008), 719–727.
52. 52 Sermet-Gaudelus, I., Boeck, K.D., Casimir, G.J., et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182 (2010), 1262–1272.
53. 53 Wilschanski, M., Miller, L.L., Shoseyov, D., et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38 (2011), 59–69.
54. 54 Kerem, E., Konstan, M.W., De Boeck, K., et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2 (2014), 539–547.
55. 55 Van Goor, F., Hadida, S., Grootenhuis, P.D., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106 (2009), 18825–18830.
56. 56 Ramsey, B.W., Davies, J., McElvaney, N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
57. 57 Davies, J.C., Wainwright, C.E., Canny, G.J., et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187 (2013), 1219–1225.
58. 58 Yu, H., Burton, B., Huang, C.J., et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 11 (2012), 237–245.
59. 59 De Boeck, K., Munck, A., Walker, S., et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13 (2014), 674–680.
60. 60 Carter, S., Kelly, S., Caples, E., et al. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. J Cyst Fibros, 2015, 10.1016/j.jcf.2015.01.010.
61. 61 Van Goor, F., Hadida, S., Grootenhuis, P.D., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 108 (2011), 18843–18848.
62. 62 Clancy, J.P., Rowe, S.M., Accurso, F.J., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67 (2012), 12–18.
63. 63 Boyle, M.P., Bell, S.C., Konstan, M.W., et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2 (2014), 527–538.
64. 64 Rosenfeld, M., Marigowda, G., Liu, F., Waltz, D., Effect of lumacaftor in combination with ivacaftor on fev1 and safety measures in patients aged 6-11 years with CF who are homozygous for F508DEL-CFTR. Pediatr Pulmonol, 49, 2014, 287.
65. 65 Elborn, J., Wainwright, C.E., Ramsey, B., et al. Effect of lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for F508DEL-CFTR: the traffic study. Pediatr Pulmonol 49 (2014), 304–305.
66. 66 Donaldson S, Pilewski J, Griese M, Dong Q, Lee PS. WS7.3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: Interim analysis. J Cyst Fibros 12 (suppl 1), 2013, S14.
67. 67 Balfour-Lynn, I.M., Personalised medicine in cystic fibrosis is unaffordable. Paediatr Respir Rev 15:suppl 1 (2014), 2–5.
68. 68 Bilton, D., Personalised medicine in cystic fibrosis must be made affordable. Paediatr Respir Rev 15:suppl 1 (2014), 6–7.
69. 69 Robertson, S.M., Luo, X., Dubey, N., et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol 55 (2015), 56–62.
70. 70 Westphal, J.F., Macrolide—induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50 (2000), 285–295.
71. 71 Monchaud, C., de Winter, B.C., Knoop, C., et al. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet 51 (2012), 175–186.